LS-P-EVOPAR

LS-P-EVOPAR: A Phase III study of novel selective PARP1 inhibitor (AZD5305) in combination with standard hormonal agents for patients newly diagnosed with metastatic castration-sensitive prostate cancer with or without DNA repair mutations.